Trastuzumab and HER2 Targeted Cancer Treatment
/ Jan Trøst Jørgensen
Advancements and Emerging Challenges in HER2-Low Treatment
/ Paolo Tarantino
DESTINY-Breast03 Study: Trastuzumab Deruxtecan versus Trastuzumab Emtansine
/ Giuseppe Curigliano